Biolife Solutions Inc
BLFS- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0000834365
No open-market purchases or sales by Biolife Solutions Inc insiders were filed in the last 90 days; 216 institutions reported holding it in 13F filings for Q2 2026, worth $1.40B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Biolife Solutions Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Biolife Solutions Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Berard Todd | Chief Marketing Officer | 161,823 | Sep 22, 2026 | 13 |
| Mathew Aby J. | EVP & Chief Scientific Officer | 387,269 | Sep 22, 2026 | 13 |
| Werner Sean | Chief Technology Officer | 47,135 | Sep 22, 2026 | 8 |
| De Greef Roderick | President and CEO | 728,196 | Sep 22, 2026 | 6 |
| Wichterman Troy | Chief Financial Officer | 211,286 | Sep 22, 2026 | 14 |
| Casdin Partners GP, LLC | 10% Owner | 4,757,165Indirect | May 21, 2026 | 2 |
| Casdin Capital, LLC | 10% Owner | 4,757,165Indirect | May 21, 2026 | 2 |
| Casdin Eli | 10% Owner | 4,757,165Indirect | May 21, 2026 | 2 |
| Casdin Partners Master Fund, L.P. | 10% Owner | 4,757,165Indirect | May 21, 2026 | 2 |
| Foster Karen A. | Chief Quality and Operations | 108,758 | Mar 31, 2026 | 9 |
| Aebersold Sarah | Chief Human Resources Officer | 92,429 | Mar 23, 2026 | 7 |
| Goswami Joydeep | Director | 53,156 | Feb 26, 2026 | 3 |
| Ellingson Rachel | Director | 57,995 | Feb 26, 2026 | 1 |
| Hunt Anthony | Director | 15,046 | Feb 26, 2026 | 1 |
| Moore Timothy L. | Director | 44,943 | Feb 26, 2026 | 1 |
| Coste Catherine | Director | 13,871 | Feb 26, 2026 | 1 |
| DuRoss Amy | Director | 26,857 | Feb 26, 2026 | 4 |
| Richardson Garrie | Chief Revenue Officer | 114,773 | Sep 18, 2024 | 0 |
| Schick Joseph C | Director | 43,953 | Mar 12, 2024 | 0 |
| Phillips Geraint | SVP, Global Operations | 65,998 | Mar 12, 2024 | 0 |
| Rice Michael | Other: Former CEO and Director | 347,085 | Nov 1, 2023 | 0 |
| Schulz Marcus | Chief Revenue Officer | 42,097 | Aug 29, 2023 | 0 |
| Hinson Andrew G | Director | 17,675 | Aug 18, 2021 | 0 |
| Cohen Raymond W | Director | 27,763 | Jul 14, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Berard ToddChief Marketing Officer | SSale | −344 | $25.59 | −$8.80K | −0.3%132.6K after | 10b5-1 |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Mathew Aby J.EVP & Chief Scientific Officer | SSale | −405 | $25.59 | −$10.4K | −0.1%349.4K after | 10b5-1 |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Aebersold SarahChief Human Resources Officer | SSale | −241 | $25.59 | −$6.17K | −0.3%75.8K after | 10b5-1 |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Foster Karen A.Chief Quality and Operations | SSale | −335 | $25.59 | −$8.57K | −0.2%192.0K after | 10b5-1 |
| Jan 8, 2026 (view filing) | Jan 6 | 2 days | Wichterman TroyChief Financial Officer | SSale | −990 | $25.59 | −$25.3K | −0.7%150.7K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Berard ToddChief Marketing Officer | SSale | −353 | $20.74 | −$7.32K | −0.2%165.9K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Aebersold SarahChief Human Resources Officer | SSale | −219 | $20.74 | −$4.54K | −0.2%93.4K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Wichterman TroyChief Financial Officer | SSale | −588 | $20.74 | −$12.2K | −0.3%220.6K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Mathew Aby J.EVP & Chief Scientific Officer | SSale | −529 | $20.74 | −$11.0K | −0.1%392.9K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Foster Karen A.Chief Quality and Operations | SSale | −418 | $20.74 | −$8.67K | −0.2%210.7K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Werner SeanChief Technology Officer | SSale | −111 | $20.74 | −$2.30K | −0.2%49.9K after | 10b5-1 |
| Mar 9, 2026 (view filing) | Mar 5-9 | 4 days | Foster Karen A.Chief Quality and Operations | SSale | −97.4K | $20.15 | −$1.96M | −46.2%113.2K after | 2 lots |
| Mar 31, 2026 (view filing) | Mar 23 | 8 daysLate | Foster Karen A.Chief Quality and Operations | SSale | −2.58K | $19.17 | −$49.4K | −2.3%108.8K after | 10b5-1 |
| May 21, 2026 (view filing)7:10 PM ET | May 19-21 | 2 days | Casdin Partners GP, LLC and 3 others10% Owner | SSaleCommon Stock, par value $0.001 per share | −1.20M | $23.44 | −$28.1M | −20.1%4.76M after | 3 lots |